Wanbury Limited Completes USFDA Inspection; Receives Form 483 with Six Observations
Wanbury Limited has completed a routine current Good Manufacturing Practices (cGMP) inspection by the United States Food and Drug Administration (USFDA). The company reported that the USFDA issued a Form 483 following the review of its manufacturing processes.The inspection took place at the company's facility located in Tanuku, West Godavari District, Andhra Pradesh. The routine cGMP assessment was conducted by the USFDA over a period spanning July 13, 2026, to July 17, 2026.
At the conclusion of the inspection, Wanbury Limited received Form 483, which contains six observations regarding its operations.
The company confirmed that it will respond to these specific observations issued by the FDA within the stipulated time frame. Wanbury Limited also stated that it will provide updates on the matter as further developments occur.
WANBURY Stock Price Movement
Today, shares of Wanbury Limited climbed, settling higher by 2.63% to close at ₹339.90. The stock traded within an intraday range of ₹331.35 and ₹346.00 before the market closed.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.